Background illustration for clinical trials search

Chronic Lymphocytic Leukemia Clinical Trials

Browse 1,522 chronic lymphocytic leukemia clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

for
Solid Tumor, Adult, Triple Negative Breast Cancer,
Location: Scottsdale AZ, La Jolla CA, Stanford CA
Sponsor: BioEclipse Therapeutics

Sex: All

Age: 18+

Code: NCT04282044

Phase 1, Recruiting

Synapse 3D With Intravascular Indocyanine Green

for
Non-small Cell Lung Cancer, Primary Neoplasm
Location: Hamilton
Sponsor: St. Joseph's Healthcare Hamilton

Sex: All

Age: 18+

Code: NCT03953144

Phase 1, Phase 2, Recruiting

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

for
Metastatic Solid Tumor, Advanced Solid Tumor
Location: Lake Success NY, New York NY, Fairfax VA, Pittsburgh PA,
Sponsor: Coherus Oncology, Inc.

Sex: All

Age: 18+

Code: NCT06657144

Phase 1, Recruiting

Comprehensive Connected Cancer Care (C4): Intervention Evaluation

for
Cancer, Health Care Utilization
Location: Lexington KY
Sponsor: Timothy Mullett

Sex: All

Age: 18+

Code: NCT06326567

Recruiting

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

for
Lymphoproliferative Disorder, Multiple Myeloma
Location: Jacksonville FL, La Crosse WI, Eau Claire WI,
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06630104

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy

for
Cancer
Location: San Francisco CA
Sponsor: CellSight Technologies, Inc.

Sex: All

Age: 18 - 65

Code: NCT03142204

Phase 1, Recruiting

Trial of DFP-14927 in Advanced Solid Tumors

for
Solid Tumor, Cancer
Location: Houston TX, Los Angeles CA
Sponsor: Delta-Fly Pharma, Inc.

Sex: All

Age: 18+

Code: NCT03943004

Phase 1, Recruiting

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

for
Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-),
Location: Hartford CT, Commack NY, Uniondale NY, Harrison NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT04165772

Phase 2, Recruiting

The Interplay Between Inborn Error of Immunity and Blood Disorders: Unravelling Immune Defects Behind Common Haematological Diseases

for
Hematologic Diseases
Location: Montreal
Sponsor: Meyer Children's Hospital IRCCS

Sex: All

Age: 0 - 25

Code: NCT06857604

Recruiting

Cancer Experience Registry (CER) for Cancer Patients and Caregivers

for
Neoplasms, Cancer, Caregiver
Location: Washington D.C. DC
Sponsor: Cancer Support Community, Research and Training Institute, Philadelphia

Sex: All

Age: 18+

Code: NCT02333604

Recruiting

A Five-Year Quality of Life Study for Cancer Patients

for
Cancer
Location: Grapevine TX
Sponsor: Constantine A. Kotsanis

Sex: All

Age: 18+

Code: NCT01539148

Recruiting

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

for
Advanced Solid Tumor
Location: San Francisco CA
Sponsor: Robert Bok, MD, PhD

Sex: All

Age: 18+

Code: NCT05599048

Phase 1, Phase 2, Recruiting

Registry Study for Radiation Therapy Outcomes

for
Neoplasms
Location: New York NY, Somerset NJ, Hampton VA, Baltimore MD,
Sponsor: Proton Collaborative Group

Sex: All

Age: 0+

Code: NCT01255748

Recruiting

Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses

for
Cancer
Location: Milwaukee WI
Sponsor: Medical College of Wisconsin

Sex: All

Age: 18+

Code: NCT05674825

Phase 1, Phase 2, Recruiting

Behaviour Change for Cancer Survivors Trial

for
Cancer, Exercise
Location: Toronto
Sponsor: University of Toronto

Sex: All

Age: 18+

Code: NCT06624930

Recruiting

Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure

for
Cardiotoxicity, Pediatric Cancer, Heart Failure
Location: San Diego CA
Sponsor: Hari Narayan

Sex: All

Age: 13 - 39

Code: NCT04262830

Recruiting

Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing

for
Cancer
Location: Columbus OH
Sponsor: Ohio State University Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT02090530

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Providence RI, New Haven CT, Miami FL, Charleston SC,
Sponsor: Eikon Therapeutics

Sex: All

Age: 18 - 70+

Code: NCT06253130

Phase 1, Phase 2, Recruiting

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

for
Solid Tumor, Adult, Refractory Cancer,
Location: Boston MA, New Haven CT, New York NY, Fairfax VA,
Sponsor: GV20 Therapeutics

Sex: All

Age: 18+

Code: NCT05669430

Phase 1, Phase 2, Recruiting

ORB-021 In Patients With Advanced Solid Tumors

for
Advanced Solid Tumors Cancer
Location: Houston TX, Scottsdale AZ
Sponsor: Orionis Biosciences Inc

Sex: All

Age: 18+

Code: NCT06607939

Phase 1, Recruiting

What is chronic lymphocytic leukemia?

Chronic lymphocytic leukemia, or CLL, is a slow growing cancer of B lymphocytes that build up in the blood, bone marrow, and lymph nodes. Most people are diagnosed around age 70, often with no symptoms; when symptoms come, they include tiredness, swollen lymph nodes, frequent infections, night sweats, and weight loss. Small lymphocytic lymphoma is the same disease when the cells sit mainly in lymph nodes, so it is studied in the same trials.

When treatment is needed, it is now mostly targeted pills: BTK inhibitors taken continuously, or venetoclax based combinations taken for a fixed time. CAR T cell therapy was approved for CLL in 2024 for people whose disease has stopped responding to both. Genetic features such as TP53 mutation, deletion 17p, and IGHV status strongly predict how CLL behaves and which trials fit. Other leukemias are on our leukemia clinical trials page.

Types of CLL clinical trials

Who can participate in CLL clinical trials?

How CLL is staged, and why it matters for trials

How to enroll in a CLL clinical trial